<http://webisa.webdatacommons.org/111702965>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/223963397>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/111702965> .
<http://webisa.webdatacommons.org/prov/428861182>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/111702965> .
<http://webisa.webdatacommons.org/111702965>	<http://www.w3.org/ns/prov#value>	"As might be expected, the Biotechnology Industry Organization (BIO), which represents companies including Novo Nordisk, Eli Lilly and Company and Sanofi Aventis immediately disputed the Express Scripts estimates, adding that they doubted the validity of the study." .
<http://webisa.webdatacommons.org/111702965>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<tudiabetes.org> .
<http://webisa.webdatacommons.org/prov/430998296>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/111702965> .
<http://webisa.webdatacommons.org/prov/431906382>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/111702965> .